Alnylam Pharmaceuticals
Case Manager (Finance)
Case Manager
Overview
Alnylam is the industry leader in the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to address the unmet needs of patients with debilitating diseases. Founded in 2002, Alnylam was built upon a bold vision of turning scientific possibility into reality, and is now advancing a robust pipeline of investigational RNAi therapeutic medicines, including five programs in late-stage development. In 2018, Alnylam received approval for our first product, the first-ever RNAi therapeutic, by the FDA in the U.S. for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults and by the European Medicines Agency in the EU for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy. Headquartered in Cambridge, Mass., Alnylam employs over 1,200 people in 18 countries and is rapidly growing globally, with additional offices in Norton, Mass., Maidenhead, U.K., Zug, Switzerland, Amsterdam, Netherlands, and Tokyo, Japan. Alnylam is proud to have been recognized as one of The Boston Globe's Top Places to Work four years in a row (2015-2018) and a Great Place to Work in the U.K. and Switzerland in 2019. Please visit www.alnylam.com for more information.
We are currently building out our US Patient Services team to provide exceptional customer service on all levels. The Case Manager (CM) will be a critical component of the patisiran commercial strategy and work in close coordination with Field Sales, Field Reimbursement, Patient Education Liaisons and Patient Advocacy Teams to support Alnylam's patient-focused vision of harnessing a revolution in biology for human health . Reporting to the Director, US Patient Services we seek experienced, passionate, patient-focused individuals committed to improving the lives of those living with hATTR amyloidosis.
The CM will be responsible for interfacing with patients affected by hATTR amyloidosis, their caregivers, and healthcare providers (HCPs), to facilitate unencumbered access to Patisiran. The CM will work collaboratively with internal and external stakeholders to meet individual patients' needs through personalized, compassionate communication and high-touch services. . He/she is responsible for engaging multiple stakeholders in support of getting appropriate hATTR individuals started on therapy and staying on therapy. The CM focuses on identifying and coordinating various services that individual patients may need to get access to therapy and recognizing and removing reimbursement barriers that prevent the individual from remaining on therapy.
The successful candidate must be passionate about science and deeply motivated by the quest of delivering value to patients and their families with the long-term success of the company in mind. He/she will be responsible for providing a smooth customer interaction from initial intake through supporting continued patient access to therapy. He/she will manage the logistical issues impacting treatment initiation and ongoing therapy. The CM demonstrates understanding of the department business objectives and measures and demonstrates strengths working independently as well as collaboratively within a highly matrixed environment.
Additional Information: Flexibility
Summary of Key Responsibilities
Qualifications
Expectations
Alnylam Pharmaceuticals is an EEO employer committed to an exciting, diverse, and enriching work environment. #LI-BS1